Sutro Biopharma, Inc.
STRO
NASDAQ·Healthcare·Biotechnology·Mkt cap $194.2M
$20.07
▼ -2.29%
P/E
-3.81
Mkt Cap
$194.2M
52-Wk Range
$7.15–$43.85
52-Week Range
$7.15 - $43.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 104.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-23.1% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying STRO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$2.33 vs -$2.19 consensus (-6.4% surprise). Revenue of $9.8M vs $12.0M expected (-17.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.4%
Revenue trend · last 2Q
—
-85%
Q1 26
Q2 26
$14.5M
$9.8M
Margins · last 2Q
Gross
100.0%
Profit
-391.6%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 13, 2026
vs Industry
How STRO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.